Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70 CAR T for CD70+ Malignant Hematologic Diseases
NCT04662294Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD70 CAR T-cells in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) (3 arms), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Nov 2021; status: recruiting.
02
Drugs
CD70 CAR T-cells
03
Conditions
acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04662294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04662294.